By Turna Ray

A decade after its launch, Genomic Health has achieved what many molecular diagnostics companies only dream of by reporting its first profitable year.

Genomic Health last week reported a net income of $4.3 million for the 12 months ended Dec. 31, 2010, compared with a net loss of $9.4 million in 2009. Full-year revenues increased 19 percent to $178 million from $150 million in 2009, while product revenue also rose 19 percent to $175 million from $146.6 million in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.